(Q67542096)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1381298%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

title

Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1381298%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

author name string

C. Gryllis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1381298

20 September 2022

M. A. Wainberg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1381298

20 September 2022

Z. Bentwich

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1381298

20 September 2022

M. Gornitsky

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1381298

20 September 2022

B. G. Brenner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1381298

20 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1381298

20 September 2022

publication date

1 September 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1381298%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Immunology

14 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1381298%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1381298%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1381298%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

page(s)

356-361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1381298%20AND%20SRC:MED&resulttype=core&format=json

Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation

14 September 2019

cites work

1 reference

12 December 2020

Lymphokine-activated killer cells in primary immunodeficiencies and acquired immunodeficiency syndrome

1 reference

12 December 2020

Human natural lymphocyte effector cells: definition, analysis of activity, and clinical effectiveness

1 reference

12 December 2020

Selective depletion of low-density CD8+, CD16+ lymphocytes during HIV infection

1 reference

12 December 2020

Characterization of functional surface structures on human natural killer cells

1 reference

12 December 2020

Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin

1 reference

12 December 2020

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

12 December 2020

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytot

1 reference

12 December 2020

In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates

1 reference

12 December 2020

NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection

1 reference

12 December 2020

Cytotoxic T lymphocytes against HIV

1 reference

12 December 2020

Cytotoxic T-cell recognition of HIV proteins and peptides

1 reference

12 December 2020

Differential susceptibilities of U-937 cell clones to infection by human immunodeficiency virus type 1

1 reference

12 December 2020

Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases

1 reference

12 December 2020

Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1 reference

12 December 2020

Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases

1 reference

12 December 2020

Biology of natural killer cells

1 reference

12 December 2020

Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals

1 reference

12 December 2020

Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell

1 reference

12 December 2020

Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus

1 reference

12 December 2020

Lymphokine-activated killer cells. Analysis of progenitors and effectors

1 reference

12 December 2020

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

1 reference

12 December 2020

The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro.

1 reference

12 December 2020

Natural killer cell infection and inactivation in vitro by the human immunodeficiency virus

1 reference

12 December 2020

Peripheral blood natural killer cell activity in human breast cancer patients and its modulation by T-cell growth factor and autologous plasma.

1 reference

12 December 2020

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

1 reference

12 December 2020

Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality

1 reference

12 December 2020

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1 reference

12 December 2020

Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1.

1 reference

12 December 2020

Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations

1 reference

12 December 2020

Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders.

1 reference

12 December 2020

Application of flow cytometry to the study of HIV infection

1 reference

12 December 2020

Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins

1 reference

12 December 2020

Susceptibility to AZT of HIV-1 variants grown in Epstein-Barr virus-transformed B cell lines

1 reference

12 December 2020

Interleukin-2 in the treatment of HIV disease

1 reference

12 December 2020

Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells

1 reference

12 December 2020

Biology and clinical relevance of human natural killer cells

1 reference

12 December 2020

Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects

1 reference

12 December 2020

Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.

1 reference

12 December 2020

HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.

1 reference

12 December 2020

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens

1 reference

12 December 2020

Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells

1 reference

12 December 2020

10.1111/J.1365-2249.1992.TB06962.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1381298%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1381298

20 September 2022

1 reference